• Safe DNA Gel Stain for RNA Workflows

  2026-08-20

  Safe DNA Gel Stain supports sensitive DNA and RNA gel analysis while enabling blue-light visualization that can help protect samples destined for cloning or sequencing. This practical guide connects routine gel quality control with advanced RNA-structure workflows, including the cgSHAPE-seq strategy used to map ligand binding in SARS-CoV-2 RNA.

• EZ Cap™ Cy5 EGFP mRNA: Delivery Workflow

  2026-08-20

  Build a quantitative mRNA delivery and translation efficiency assay around one reporter that separates cellular uptake from functional EGFP expression. The dual-fluorescence design supports nanoparticle screening, macrophage-focused delivery studies, and troubleshooting of intracellular trafficking without relying on secondary labeling.

• Deferasirox Fe3+ Chelate for Iron Research

  2026-08-19

  Build reproducible iron-binding, cell-response, and translational assays with Deferasirox Fe3+ chelate, while accounting for its pre-formed ferric complex and DMSO-dependent handling. The workflow connects Exjade-related clinical evidence with practical beta-thalassemia iron chelation and chronic anemia iron management experiments.

• From Diuron Signals to qPCR Translation

  2026-08-19

  A translational framework for using SYBR Green qPCR to validate diuron-associated osteotoxicity signals, connect BMSC phenotypes with PI3K/Akt biology, and build more reproducible environmental toxicology workflows with HotStart™ 2X Green qPCR Master Mix.

• MRT68921 ULK1 Kinase Inhibitor: Workflow Guide

  2026-08-18

  MRT68921 enables controlled, pathway-level autophagy inhibition by targeting both ULK1 and ULK2, making it useful for dissecting initiation signals, energy-stress responses, and LC3 flux. This practical guide covers dosing design, ATG13 phosphorylation blockade, assay controls, and troubleshooting for reproducible cell-based studies.

• Sex Differences in Angiotensin II Hypertension

  2026-08-17

  This reference study used telemetry in conscious, freely moving mice to show that chronic angiotensin II produces a substantially greater hypertensive response in males than females. Gonadectomy, baroreflex testing, and ganglionic blockade further implicated sex hormones and sympathetic regulation, providing a useful framework for sex-aware cardiovascular study design.

• Marein Inhibits ABCG2 and Restores Chemosensitivity

  2026-08-17

  The reference study identifies marein, a flavonoid from Coreopsis tinctoria Nutt, as a competitive inhibitor of the ABCG2 drug efflux transporter. By increasing intracellular exposure to ABCG2-substrate chemotherapeutics and sensitizing resistant cancer cells, the work provides a mechanistic framework for transporter-directed chemosensitization.

• PEI-Modified Laminarin Nanoparticles Boost OVA Vaccination

  2026-08-16

  The reference study develops cationic laminarin nanoparticles by polyethyleneimine modification and uses them to deliver ovalbumin as a model antigen. The formulation improves dendritic-cell uptake, maturation, lysosomal escape, antigen cross-presentation, and downstream humoral and cellular immunity compared with an aluminum adjuvant.

• Small-Molecule LAG-3 Inhibitors: Study Insights

  2026-08-15

  The 2023 ACS Medicinal Chemistry Letters study combines focused screening with SAR by catalog to identify a small molecule that inhibits both LAG-3/MHC class II and LAG-3/FGL1 interactions. Its biochemical and cell-based results establish an early proof of concept for dual LAG-3 blockade, while also defining the selectivity, pharmacology, and translational studies still needed.

• Tacrolimus (FK506) as a Causal Probe of T-Cell Signaling

  2026-08-15

  Tacrolimus (FK506) is more than a potent calcineurin inhibitor: it is a precise causal probe for connecting FKBP12 complex formation to NFAT-dependent cytokine output. This article translates genetic evidence from cyclosporine research into rigorous assay design for transplantation immunology research and autoimmune disease models.

• uPAR–uPA Inhibition in Breast Cancer Metastasis

  2026-08-14

  The reference study advanced compound 4 from a computationally identified protein–protein interaction hit to a chemically synthesized and biologically validated inhibitor of uPAR–uPA signaling. Direct binding, cellular invasion assays, pharmacokinetics, and a murine metastasis model together support compound 4 as a lead template, while also defining important limitations for translation and assay replication.

• N6-Methyl-dATP for DNA Fidelity Workflows

  2026-08-14

  N6-Methyl-dATP enables controlled testing of how an adenine methylation changes polymerase recognition, incorporation, and downstream DNA analysis. This workflow-centered guide connects biochemical fidelity assays with the LMO2–LDB1 AML literature while emphasizing controls, storage, optimization, and interpretation limits.

• Biomimetic Chromatography for Lung Permeability

  2026-08-13

  Dillon and colleagues compared mass-spectrometry-compatible immobilised artificial membrane liquid chromatography and open-tubular capillary electrochromatography for modelling pulmonary drug permeability. The study shows that the platforms provide complementary information on lipid partitioning and drug–membrane interactions, supporting faster permeability screening while highlighting the need for compound- and ionisation-specific interpretation.

• CFDA SE Cell Tracer Kit: Practical Guide

  2026-08-13

  The CFDA SE Cell Tracer Kit provides stable fluorescent labeling for monitoring labeled cell populations across cell proliferation studies and cell lineage tracing workflows. It is suited to durable in vitro or in vivo tracking, but not to reversible labeling, rapid washout, or real-time physiological monitoring.

• Baricitinib (LY3009104): JAK1/2 Research Guide

  2026-08-12

  Baricitinib, also called LY3009104, is an orally bioavailable, ATP-competitive inhibitor with strong biochemical activity against JAK1 and JAK2. Its research value lies in testing JAK1/2-dependent cytokine signaling, STAT3 phosphorylation, and inflammatory phenotypes without equating pathway inhibition with proof of therapeutic efficacy.

432 records 6/29 page Previous Next First page 上5页 678910 下5页 Last page